ClinicalTrials.gg
Not yet recruitingNCT07715253Updated Jul 20, 2026

Longitudinal PET Imaging of Antipsychotic Binding to the Dopamine-3 Receptor in Schizophrenia

A Phase 1 interventional study of Brexpiprazole and Cariprazine in Schizoaffective Disorder, Schizophreniform Disorder and Schizophrenia, sponsored by New York State Psychiatric Institute. Not yet recruiting. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-07-20.

Sponsored by New York State Psychiatric Institute · Phase 1, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 25 studies in Psychotic Disorders by New York State Psychiatric Institute — 4 open to participants now, 4 under way, none of them phase 3. Psychotic Disorders · New York State Psychiatric Institute.

Planned enrollment
8th of 23
100 · median 60
Started
2026
the only one that year
Phase 1
3 of 25
1 open now
Registered
25th of 25
by date

Among the 25 studies in Psychotic Disorders by New York State Psychiatric Institute, this one is the 8th largest by planned enrollment of the 23 interventional ones that give a count, is the only one that started in 2026, is one of 3 in phase 1, and was the 25th registered.

Psychotic Disorders

1,593 studies on the registry are indexed under Psychotic Disorders; 283 are open to participants now.

Browse Psychotic Disorders studies →

Open to participants now

4 of the 25 studies in Psychotic Disorders by New York State Psychiatric Institute are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 204 Psychotic Disorders studies recruiting now, 53 (26%) set no upper age limit and 142 (70%) stop at 75 or younger; 50 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Psychotic Disorders by New York State Psychiatric Institute, or all of them as a file.
02

Study summary

This is a clinical trial in which 40 participants with schizophrenia will be randomized to 15 days of treatment with cariprazine (CAR) or brexpiprazole (BREX) in a single-blind manner. [11C]PHNO PET scans will be obtained before treatment and after 1 day and 15 days of treatment to examine the effects of antipsychotic medications on the dopamine-3 receptor (D3R). The overall objectives of the current study are to: 1) measure the acute binding of CAR/BREX to the D3R; 2) measure D3R availability for evidence of upregulation following subchronic administration of CAR/BREX in the same set of patients; 3) examine relationships between subchronic binding of CAR/BREX to, and upregulation of, the D3R vs. D2R and changes in positive symptoms, negative symptoms, and cognitive deficits. Relationships between subchronic binding of CAR/BREX and EPS will be explored.

Read the detailed description

There is a great need for the development of new treatments for schizophrenia (SCZ). Aside from the recently approved muscarinic agonist xanomeline, all current treatments have been assumed to function by blocking dopamine-2 receptors (D2Rs). Interest in the dopamine-3 receptor (D3R) was encouraged by preclinical findings that D3R antagonists reverse cognitive impairment and improve negative symptoms. In vivo imaging of the D3R became possible with the development of [11C]-(+)-PHNO, a D3R-preferring radioligand. However, while numerous preclinical studies have demonstrated that the D3R is relevant to both the neurobiology and treatment of SCZ, in vivo studies initially and surprisingly reported that, after several weeks of administration, antipsychotic medications may not bind to the D3R and may paradoxically increase levels of the D3R. These findings were discrepant with our own findings in non-human primates and individuals with SCZ demonstrating that acute doses of antipsychotic medications bind to the D3R and D2R in ratios predicted by their in vitro binding profiles. In a later study conducted by our group, 10 days of chronic dosing of the D2R-preferring antipsychotic medication brexpiprazole (BREX) also led to increased levels of the D3R at 1mg and negligible binding at 4mg. Finally, in our study of the D3R-preferring antipsychotic medication cariprazine (CAR), there was robust binding to the D3R and D2R after both acute and subchronic dosing. These seemingly discrepant findings may be related to methodological differences, differences in the binding profiles of D2R- vs. D3R-preferring antipsychotic medications, or to homeostatic responses to chronic antipsychotic treatment (i.e., upregulation). Upregulation is a potentially critical, though underexamined, effect common to all D2R/D3R-binding antipsychotic medications, including partial agonists. It has been hypothesized to be largely responsible for differences in occupancy estimates from single and repeat dose studies and contribute to waning effects of antipsychotic medications and tardive dyskinesia. The goals of this proposal are to elucidate the contribution of D3R, compared to D2R, binding to antipsychotic action, both acutely (SA1) and subchronically (SA2), in the same patients. The relationship between occupancy, upregulation, and clinical effects (SA3, EA) will be investigated.

03

Conditions studied

  • Schizoaffective Disorder
  • Schizophreniform Disorder
  • Schizophrenia

Keywords

  • schizophrenia
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Individuals, any gender or sex, aged 18 to 55, inclusive at screen
  2. Capable of understanding the study procedures and able to provide
  3. Diagnosed with schizophrenia, schizoaffective, or schizophreniform disorder
  4. Negative urine toxicology
  5. Antipsychotic free (by choice and for reasons unrelated to the study), and for at least 3 weeks (4 for aripiprazole or LAIs) at the time of the baseline PET scan, inclusive of any antipsychotic-free time prior to consent. [Any patient who requires inpatient hospitalization or acute medication treatment for clinical stabilization during the medication free period will not be included in this study; any participant who in the clinical judgment of the PIs or any involved clinician is not stable or appropriate for a medication free period will not be included.]
  6. PANSS total score > 80 and \< 120 (inclusive)

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of substance use disorder within the previous month
  2. A history of poor or inadequate response or to CAR or BREX for any reason
  3. abnormality that is including a > 450 msec for men and > 470 msec for women,
  4. Pregnant or breast-feeding women. Women of must have a negative serum β-hCG pregnancy test at Visit 1, must have been using an acceptable method of for 30 days before the study (i.e., before the first PET or MRI scan, whichever comes first), and must agree to do so for the whole study and 30 days after (unless or surgically sterile)
  5. Any clinically significant or unstable medical/neurological illness, condition, or disorder that is anticipated to potentially compromise participant safety on study medication
  6. Any material in the body that is a for MRI procedures or participated in prior nuclear medicine procedures in the past year that exceed FDA-defined limits when combined with radiation dosimetry from PET scanning in this protocol to avoid exceeding annual dosimetry limits (metal screener repeated before MRI scan). Individuals exposed to radiation in the workplace in the previous year will be excluded.
  7. Acute risk for suicide (i.e., score of 4-5 within the previous month or 6 within the previous 3 months on the CSSRS) or violence/homicide (e.g., homicidal ideation), or history of severe violent behavior or behavioral dyscontrol while antipsychotic-free
  8. A history of treatment resistance to antipsychotics or who have a duration of illness of greater than 20 years
  9. Claustrophobia
  10. Use of nicotine products within the previous month (prior to first PET scan)
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Cariprazine 1mg

    Cariprazine 1mg daily for 15 days

    Drug: Cariprazine · Drug: [11C] PHNO

  • Experimental
    Cariprazine 2mg

    Cariprazine 2mg daily for 15 days

    Drug: Cariprazine · Drug: [11C] PHNO

  • Experimental
    Cariprazine 3mg

    Cariprazine 3mg daily for 15 days

    Drug: Cariprazine · Drug: [11C] PHNO

  • Experimental
    Cariprazine 4mg

    Cariprazine 4mg daily for 15 days

    Drug: Cariprazine · Drug: [11C] PHNO

  • Experimental
    Brexpiprazole 1mg

    Brexpiprazole 1mg daily for 15 days

    Drug: Brexpiprazole · Drug: [11C] PHNO

  • Experimental
    Brexpiprazole 2mg

    Brexpiprazole 2mg daily for 15 days

    Drug: Brexpiprazole · Drug: [11C] PHNO

  • Experimental
    Brexpiprazole 3mg

    Brexpiprazole 3mg daily for 15 days

    Drug: Brexpiprazole · Drug: [11C] PHNO

  • Experimental
    Brexpiprazole 4mg

    Brexpiprazole 4mg daily for 15 days

    Drug: Brexpiprazole · Drug: [11C] PHNO

Interventions

  • Brexpiprazole is an antipsychotic medication

  • Cariprazine is an antipsychotic medication

  • Drug[11C] PHNO

    This is the radiotracer that will be used to examine antipsychotic binding to D2 and D3 receptors in this study. It is experimental and used for imaging purposes.

06

What researchers measure

Primary outcomes

  1. Acute D2 and D3 Receptor Occupancy

    Delta BPND in poscommissural putamen and midbrain

    Time frame: Day 1

  2. Upregulation of D3 receptor following subchronic administration of antipsychotics

    The availability of D3Rs following two weeks of antipsychotic treatment will be measured.

    Time frame: Day 15

Secondary outcomes

  1. Positive and Negative Syndrome Scale (PANSS) Total Positive Symptoms

    Correlations between changes in PANSS total positive symptoms and receptor binding will be examined.

    Time frame: 15 days

  2. Positive and Negative Syndrome Scale (PANSS) Total Negative Symptoms

    Correlations between changes in PANSS total negative symptom scores and receptor binding will be examined.

    Time frame: 15 days

  3. MATRICS Cognitive Deficits (Composite Score)

    Correlations between changes in cognitive deficits (MATRICS composite score) and receptor binding will be examined.

    Time frame: 15 days

Other outcomes

  1. Abnormal Involuntary Movement Scale (AIMS) Score

    Correlations between changes in extrapyramidal side effect scores (AIMS) and receptor binding will be examined.

    Time frame: 15 days

  2. Simpson-Angus Scale (SAS) Score

    Correlations between changes in extrapyramidal side effect scores (SAS) and receptor binding will be examined.

    Time frame: 15 days

  3. Barnes Akathisia Rating Scale (BARS) Score

    Correlations between changes in extrapyramidal side effect scores (BARS) and receptor binding will be examined.

    Time frame: 15 days

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — Data will be shared via the NIH data archive.

Time frame: Data will be shared after the study has been completed, as per NIH guidelines.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Aug 2030, 44 months later.

Of 28 phase 1 interventional studies under Psychotic Disorders, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 55. This study's planned 44 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2026
First posted
Jul 20, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Aug 30, 2030
CompletionEst.
Nov 30, 2030
Last update
Jul 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07715253
Responsible party
Ragy Girgis (Professor of Clinical Psychiatry, New York State Psychiatric Institute) — Principal investigator
First posted
Jul 20, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Aug 30, 2030 (estimated)
Completion
Nov 30, 2030 (estimated)
Last update
Jul 20, 2026

Study contacts

Ragy Girgis, MD
Contact
ragy.girgis@nyspi.columbia.edu
646-774-5553

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Brexpiprazole · Cariprazine

Start the discussion